|Articles|August 1, 2004

Supplements and Featured Publications

  • Newsletter - Inflammation, Metabolic Syndrome, and CV Risk Reduction
  • Volume 10
  • Issue 2 Metab

Faculty Disclosure Statement

Dr Dunbar: Speakers' bureau: Kos, Pfizer; Dr Szapary: Grants/research support: Takeda; Speakers' bureau: Takeda, Pfizer; Dr Haffner: Reported no financial support; Dr Rader: Consultant/grants/research support: Abbott, AstraZeneca, Bristol-Myers Squibb, Fournier, Kos, Merck, Pfizer, Schering-Plough; Speakers' bureau: Abbott, AstraZeneca, Bristol-Myers Squibb, Kos, Merck, Pfizer, Schering-Plough.

This report includes discussion of insulin sensitizers, including metformin and the thiazolidinediones, for preventing type 2 0diabetes, an indication not currently approved by the FDA.

Articles in this issue

about 21 years ago

CE / CME

about 21 years ago

Commentary

about 21 years ago

Post Test

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo